Brexpiprazole (Major Depressive Disorder) Market Size, Share, Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast To 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023. Otsuka Pharmaceutical initially developed Brexpiprazole but in 2011, the pharmaceutical company entered an agreement with Lundbeck for the co-development and co-commercialization of this product. The product is in Phase III development as an adjunctive therapy for MDD in the US and Europe, and is also being developed for the treatment of schizophrenia, anxiety disorders, dementia, post-traumatic stress disorder (PTSD), sleep disorders, and ADHD. Browse the full “Brexpiprazole Market� report at: http://www.radiantinsights.com/research/brexpiprazole-major-depressive-disorderforecast-and-market-analysis-to-2023 Scope - Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Brexpiprazole including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Brexpiprazole for the top eight countries from 2013 to 2023. - Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia. Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Brexpiprazole performance - Obtain sales forecast for Brexpiprazole from 2013-2023 in the top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia). Table OF Content: 1 Table of Contents 5 1.1 List of Tables 7 1.2 List of Figures 8 2 Introduction 9 2.1 Catalyst 9 2.2 Related Reports 9 2.3 Upcoming Related Reports 11 3 Disease Overview 12 3.1 Etiology and Pathophysiology 12 3.1.1 Etiology 12 3.1.2 Pathophysiology 12 3.2 Classification 14 3.3 Symptoms and Subtypes of Major Depressive Disorder 16 3.4 Prognosis 17 3.5 Quality of Life 17 Browse All Reports of This Category @ http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare 4 Disease Management 18 4.1 Diagnosis and Treatment Overview 18 4.1.1 Diagnosis 18 4.1.2 Treatment Guidelines and Leading Prescribed Drugs 19 4.1.3 Clinical Practice 22 5 Competitive Assessment 27 5.1 Overview 27 6 Unmet Needs and Opportunities 29 6.1 Overview 29 6.2 More Effective Pharmacotherapies 30 6.2.1 Unmet Needs 30 6.2.2 Gap Analysis 31 6.2.3 Opportunities 32 6.3 More Favorable Side Effect Profiles 32 6.3.1 Unmet Needs 32 6.3.2 Gap Analysis 33 6.3.3 Opportunities 33 6.4 Rapid Onset of Antidepressant Effects 34 6.4.1 Unmet Needs 34
6.4.2 Gap Analysis 34 6.4.3 Opportunities 34 6.5 Personalized Treatment Approach 35 6.5.1 Unmet Needs 35 6.5.2 Gap Analysis 36 6.5.3 Opportunities 36 7 Pipeline Assessment 37 7.1 Overview 37 7.2 Promising Drugs in Clinical Development 37 8 Brexpiprazole (OPC-34712) 40 8.1 Overview 40 8.2 Efficacy 42 8.3 Safety 43 8.4 Dosing and Formulation 44 8.5 Potential Clinical and Commercial Positioning 45 8.6 SWOT Analysis 46 8.7 Forecast 46 9 Appendix 48 9.1 Bibliography 48 9.2 Abbreviations 52 9.3 Methodology 55 Request Free Sample Of This Study @ http://www.radiantinsights.com/research/brexpiprazole-major-depressive-disorderforecast-and-market-analysis-to-2023#tabs-4 9.4 Forecasting Methodology 55 9.4.1 Diagnosed MDD Patients 55 9.4.2 Percent of Drug-Treated Patients 55 9.4.3 General Pricing Assumptions 56 9.4.4 Generic Erosion 57 9.4.5 Pricing of Pipeline Agents 57 9.5 Physicians and Specialists Included in this Study 58 9.6 About the Authors 60 9.6.1 Analyst 60 9.6.2 Therapy Area Directors 60 9.6.3 Global Head of Healthcare 61 9.7 About GlobalData 62 9.8 Disclaimer 62
About Us Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of Ancillary services such as, research partnerships/ tie-ups and customized research solutions. Media Contact: Michelle Thoras Corporate Sales Specialist, USA Radiant Insights, Inc Phone: 1-415-349-0054 Toll Free: 1-888-202-9519 Email: sales@radiantinsights.com Website: Radiant Insights Visit Our Blog: radiantri.blogspot.com